{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:24:38Z","timestamp":1750494278102,"version":"3.28.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.urology.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:41:00Z","timestamp":1716003660000},"page":"79-84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer"],"prefix":"10.1016","volume":"191","author":[{"given":"Rishi R.","family":"Sekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarosh","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Maganty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey A.","family":"Herrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.05.006_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"year":"2023","series-title":"Cancer facts & figures 2023","author":"American Cancer Society","key":"10.1016\/j.urology.2024.05.006_bib2"},{"issue":"9","key":"10.1016\/j.urology.2024.05.006_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.urology.2024.05.006_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomized, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.urology.2024.05.006_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.urology.2024.05.006_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urology.2024.05.006_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2024.05.006_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4111\/icu.20200132","article-title":"Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer","volume":"61","author":"McFerrin","year":"2020","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urology.2024.05.006_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.05.006_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11934-019-0950-0","article-title":"Disparities in bladder cancer outcomes based on key sociodemographic characteristics","volume":"21","author":"Yip","year":"2020","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2024.05.006_bib11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.05.006_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-011-0709-9","article-title":"Impact of gender on bladder cancer incidence, staging, and prognosis","volume":"29","author":"Fajkovic","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2024.05.006_bib13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/cncr.32048","article-title":"Delays in radical cystectomy for muscle-invasive bladder cancer","volume":"125","author":"Chu","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.05.006_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/BLC-160058","article-title":"The relationship between centralization of care and geographic barriers to cystectomy for bladder cancer","volume":"2","author":"Casey","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urology.2024.05.006_bib15","unstructured":"Centers for Disease Control and Prevention\/ Agency for Toxic Substances and Disease Registry\/ Geospatial Research, Analysis, and Services Program. CDC\/ATSDR Social Vulnerability Index [2018] Database [UnitedStates]. Accessed February 1, 2023. \u3008https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/data_documentation_download.html\u3009."},{"key":"10.1016\/j.urology.2024.05.006_bib16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10552-023-01683-1","article-title":"The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping review","volume":"34","author":"Tran","year":"2023","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.urology.2024.05.006_bib17","unstructured":"HUD USPS zip code crosswalk files. Office of Policy Development and Research. Accessed November 27, 2022. \u3008https:\/\/www.huduser.gov\/portal\/datasets\/usps_crosswalk.html\u3009."},{"key":"10.1016\/j.urology.2024.05.006_bib18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1377\/hlthaff.2022.00482","article-title":"Use of area-based socioeconomic deprivation indices: a scoping review and qualitative analysis","volume":"41","author":"Trinidad","year":"2022","journal-title":"Health Aff"},{"key":"10.1016\/j.urology.2024.05.006_bib19","doi-asserted-by":"crossref","first-page":"164.e17","DOI":"10.1016\/j.urolonc.2021.12.004","article-title":"Treatment disparities in muscle-invasive bladder cancer: evidence from a large statewide cancer registry","volume":"40","author":"Shah","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.05.006_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2023.02.045","article-title":"Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer","volume":"177","author":"Miller","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.05.006_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/UPJ.0000000000000200","article-title":"Understanding the barriers to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer: a quality improvement initiative","volume":"8","author":"Andino","year":"2021","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2024.05.006_bib22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524003595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524003595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:10:54Z","timestamp":1730463054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524003595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":22,"alternative-id":["S0090429524003595"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.05.006","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}